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In the following a brief commentary is given on a new European project that aims to provide the European
countries with recommendations for the care of children and yound adults with rheumatic diseases. These
recommendations will be based on surveys sent to PRINTO members and systematic literature reviews. Surveys on
current local standard of care and best practice will be send to PRINTO members in EU member states. The success
of this project largely largely depends on information provided by individual centers from our existing PRINTO and
PReS networks. We would therefore like to ask your collaboration in completing and returning these surveys which
will be circulated March April 2013.In the course of 2013 a new European project called
SHARE will be launched involving the pediatric rheuma-
tology networks in all European Union members states
and candidate member states with the aim to describe
what is needed for optimal care for children and young
people with rheumatic disease. This will be done using
surveys that are sent to individual centers and
organizations throughout Europe. The success of the
project as described below largely depends on the col-
laboration from pediatric rheumatologists, allied health
care professionals, parents and patient organizations. For
a detailed overview of the current delivery of clinical
care services, it is important that there is a high re-
sponse rate with completion of as much data as possible.
With this in mind, we provide a brief description of aims
and future collective benefits of the SHARE initiative.Pediatric rheumatology in Europe: dealing with
rare diseases
In April 2012, the European Agency for Health and
Consumers (EAHC) signed the contract for a new
European initiative for children and young persons with
rheumatic diseases. The project description is “Single
Hub and Access point for paediatric Rheumatology in
Europe (acronym SHARE, project number 2011 1202,
Project Coordinator NM Wulffraat). A specific problem
for rare diseases is that their low prevalence hinders
sound and representative research. As a consequence
there is a lack of evidence based guidelines for disease* Correspondence: n.wulffraat@umcutrecht.nl
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distribution, and reproduction in any medium(and pain) management of Pediatric Rheumatic Diseases
(PRD) and treatment is mostly based on anecdotal
observations and experience accrued by clinicians [1].
Therefore PRD treatment differs substantially throughout
Europe and even within a single country. The inter-
national organizations for pediatric rheumatologists in
Europe and the US, (PReS and PRCSG) have acknowl-
edged this problem and jointly produced recently several
recommendations in Juvenile Idiopathic Arthritis [2,3]. In
addition, EULAR (see www.eular.org) promotes efforts to
produce recommendations [4].
There is thus a need for standardized diagnosis and
management of PRD throughout Europe. PRDs include
both pediatric rheumatic autoimmune diseases and auto-
inflammatory diseases. We expect sizable differences
between institutions as well as differences between West
and East Europe. Although valuable work on PRD is
emerging - and has been - performed by various initiatives
on both a national and a European level there is a clear
need for facilitating better access to information by
combining the expertise, the knowledge and resources
available in Europe for individual diseases in one single
PRD initiative. The resulting information network would
facilitate sharing knowledge and expertise which can fa-
cilitate research initiatives to significantly improve the
desired healthcare delivery in PRD.
The European Union has recognized this problem and
states in its European Charter of patients’ rights (http://
ec.europa.eu/health/ph_overview/co_operation/mobility/
docs/health_services_co108_en.pdf) that “Despite their
differences, national health systems in European Union
countries place the same rights of patients, consumers,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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people at risk. Despite solemn declarations on the
European Social Model (the right to universal access to
health care), several constraints call the reality of this
right into question. As European citizens, we do not
accept that rights can be affirmed in theory, but then
denied in practice, because of financial limits. Financial
constraints, however justified, cannot legitimize denying
or compromising patients’ rights” [5].
Project description
The main goals are to summarize the needs for uniform
management of rare pediatric rheumatic diseases through-
out Europe, to provide recommendations for management
of these diseases in European countries on which optimal
treatment is based, to update the existing website with
interactive tools and updated patient information, to pro-
vide a proposal for state of art postgraduate education and
training for health care professionals dealing with these
diseases (see Table 1). In short the aim of this project is to
define what we need in order to provide optimal care to
children with PRD in EU member and candidate member
states. As is custom in European projects, Work Packages
(WP) were formed to address these aims. Work packages
1–3 deal with management, dissemination of results and
evaluation and will not be discussed in this paper.
Defining the need for optimal care of PRD is the aim
of a WP4, led by Pavla Dolazalova (Prague, Czech
Republic). This WP will provide recommendations based
on a detailed evaluation of current standards of care,
access to care, and protocols. A good example of this is
the recently published BSPAR (British Society forTable 1 AIMS of the European SHARE project
Identifying the specific needs for optimal care in PRD in each EU






Identifying best practices and establishing minimal standards of care






Establishing platforms for the exchange of information, data and
samples and for linking the existing networks and projects. Ensuring
a better foothold of PRD patients in both research and treatment








Identifying best practices for obtaining ethical consent and for data







Ensuring implementation of the best practices for training





Legend: PRD, Pediatric Rheumatic Diseases; WP, Work Package.Paediatric and Adolescent Rheumatology) guidelines for
the UK [6]. This overview will be based on the results of
a survey that will be send to all pediatric rheumatology
centers, including (but not limited to) the members of
PReS and PRINTO networks. The survey will include all
major PRDs. Question listed in this survey were
provided by the members of the existing PReS working
of the groups for JIA, SLE, JDM, Vasculitis and Periodic
Fevers who are involved in the Share project.
To obtain a balanced representation from all parts of
Europe we invited members of the existing PRES network
to participate in the project (see list of participants of the
SHARE consortium). Especially in countries with rela-
tively few PReS members (such as in Eastern European
countries) we will seek participation by additional centers
providing care to children with PRD, such as adult rheum-
atological clinics.
WP5 (Bas Vastert, Utrecht, Netherlands) will address the
issue of identifying best practices for treatment of paediatric
patients suffering from PRDs: the activities within this goal
start with a literature overview (as described in the EULAR
method for achieving recommendations Guidelines on
treatment of patients) by groups of experts from the PReS
working groups [7]. After completing a systematic litera-
ture review, the available evidence will be graded, by
organizing consensus meetings. Using the Delphi method
consensus will be achieved on the minimum standards of
care in PRD treatment.
WP6 (Nicola Ruperto, Genoa, Italy) will update a
central platform for data collection and analysis and for
sharing of information both for health care professionals
and patients. The PRINTO and PReS are the largeste goal is to identify the specific needs for optimal care in PRD in each
country. Optimal care includes diagnosis, management of disease and
oviding both drug- and non-drug therapies. The country specific needs
ould be identified within 18 months after the start of the project.
ter completing a systematic literature review on treatment of PRD, the
ailable evidence will be graded by organizing consensus meetings.
e best practices identified should provide for minimal standards of care
the treatment of PRD throughout Europe
portal within the PReS site will link with existing registers, projects, etc.
ultaneously we will harmonize the way in which information is stored
providing for best practices and patient information. We will provide
tients with knowledge on their diseases, treatment and research, provide
cess to patient specific networks including a platform for patients to
press their views and provide feedback from parents on this project
a inclusion of patients in this project).
entify best practices for obtaining ethical consent, data and sample
llection. These actions are aimed at enforce the exchange of these
ta and samples between European centres and should increase the
ailability of data to facilitate performing large clinical studies more
fectively.
e goal is to disseminate up-to-date knowledge on PRD to healthcare
ofessionals by providing a proposal for state of art postgraduate
ucation. This proposal should be available at the end of the project.
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uk and http://www.PRINTO.it). Activities within this
WP are building further on an earlier EU SANCO grant
with which patient information on PRD was doc-
umented and translated into all EU languages [8]. The
PRINTO website providing that information is very
succesfull, with around 11000 visitors per day. The PReS
and PRINTO websites (http://www.pres.org.uk) is cur-
rently lacking sections on best practices, standards of
care, interactive data comparison, and collaborative re-
search projects. The idea is to strongly improve the web-
site and to establish a network for data collection and
analysis, to link existing networks such as the existing
national JIA registers, and to provide tools for interactive
use of this section that will enable benchmarking of local
practices. The objective of providing a better foothold of
patients in both research and treatment will be achieved
by inclusion of patients and parents in the expert groups
so that patients have direct influence on the results of
the project. At the same time we want to improve a
patients’ access to information and the ties between
patients and their healthcare providers. This will be
achieved by introducing better ways to disseminate the
content through specific Google related techniques and
social media that will make the website more visible in-
cluding patient outreach in partnership with EURORDIS
through its RareConnect (www.rareconnect.org) portal
as well as its digital and social media presence.
A specific WP is devoted to making an inventory of
national legal guidance within the EU (candidate) mem-
ber states. Our experience is that the existing differences
can impair international clinical research involving
children [9]. The WP7 (Jasmin Kummerle-Deschner,
Tübingen, Germany) will identify best practices for
obtaining ethical consent from parents, children and
adolescents, and for data and sample collection. To
achieve this goal an analysis of ethical and legal issues
surrounding data collection and procedures for informed
consent will be performed. We will address our questions
to national EU competent health authorities, local medical
ethical committees and health care professionals. The
results will be discussed in expert meetings in order to
establish best practices for data exchange, the storage and
shipment of DNA and viable cells.
Training and education is addressed in WP8 (Alberto
Martini, Genoa, Italy). The aim here is to ensure the
implementation of the best practices identified by the
project by inclusion of the project’s results in training
programmes. Based on a survey for existing national and
international training programmes, a proposal will be
drawn up for inclusion of the results in the existing
training programme of PReS and its members. This pro-
posal will be discussed with experts in a plenary session.
The initiative will closely interact with the EULARprogramme on accredited online educational courses
(see www.eular.org), which will be a major activity for
the PRES council in the next years [10].
Time lines of the surveys in this project
Invitations to all PRINTO centers to complete this survey
on current standards of care will be send early april 2013.
We ask the respondents to complete their responses
before july first, 2013. Results will be communicated early
2014 and during the annual PRES meetings. The project
funding ends September 2015.
In summary, the SHARE initiative will circulate sur-
veys to centers and organisations involved in providing
care for children with PRD. Such surveys will form the
basis of a thorough inventory of current local practice.
From these a set of international best practices will be
selected by. These practices will be presented to
stakeholders such as health authorities, individual
centers for pediatric rheumatic diseases, health care in-
surance companies and patient/parent organisations.
The success of this project largely largely depends on in-
formation provided by individual centers from our
existing PRINTO and PReS networks.
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